CASI Pharmaceuticals, Inc.

CASIF · OTC · China

Share price · CASIF

$0.14+0.00 (+0.00%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CASIF's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 7 Jul 2026-35.0%
  2. 6 Jul 2026+33.3%
  3. 2 Jul 2026-37.5%

    Nothing announced by CASIF that day or the session before.

  4. 1 Jul 2026+41.2%

    Nothing announced by CASIF that day or the session before.

  5. 30 Jun 2026+41.7%
  6. 24 Jun 2026-33.3%
  7. 12 Jun 2026+42.9%

    Nothing announced by CASIF that day or the session before.

  8. 11 Jun 2026+27.3%
  9. 9 Apr 2026-29.4%

    Nothing announced by CASIF that day or the session before.

  10. 31 Mar 2026-31.3%

    Nothing announced by CASIF that day or the session before.

Share of unusual movement by asset

For each asset, the share of CASIF's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
CID-103
events and moves
2shown from 8 days
melphalan hydrochloride (Evomela)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—5%
Other company news (earnings, financing, releases naming no asset)—22%
Sessions with no dated event—73%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
DNA (guanine N7 position)Small molecule
Multiple Myeloma
Autologous Stem Cell Conditioning in Multiple Myeloma
Phase 2
CD38Monoclonal antibody
Multiple MyelomaImmune Thrombocytopenia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
November 2028 (1)
CID-103Phase 2Chronic Immune Thrombocytopenia
Est. primary completion 2028-11-30 · NCT07946549 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
CID-103Phase 1/2Antibody Mediated Rejection
Est. primary completion 2030-05 · NCT07641426 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$21M$6.3M$5.6M$12M-$21M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$29M$8.9M$13M$9.8M-$29M operating cash flowreport ↗
2023-FY$34M$9.9M$17M+ $12M short-term inv.$6.7M-$20M operating cash flowreport ↗
2022-FY$43M$16M$47M+ $2.8M short-term inv.$10M-$21M operating cash flowreport ↗
2021-FY$30M—$39M+ $9.9M short-term inv.$9.2M-$27M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

No Form 4 transactions on file in the stored window.